• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    2/8/24 4:16:56 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHVS alert in real time by email
    SC 13G/A 1 d582194dsc13ga.htm SC 13G/A SC 13G/A

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    Pharvaris, N.V.

    (Name of Issuer)

    Ordinary Shares

    (Title of Class of Securities)

    N69605108

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. N69605108    Schedule 13G    Page 1 of 6

     

     1   

     Names of Reporting Persons

     

     LSP V Coöperatieve U.A.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     The Netherlands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     3,556,805

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     3,556,805

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,556,805

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     6.8%

    12  

     Type of Reporting Person

     

     OO (Limited Liability Company)

     


    CUSIP No. N69605108    Schedule 13G    Page 2 of 6

     

     1   

     Names of Reporting Persons

     

     LSP V Management B.V.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     The Netherlands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     3,556,805

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     3,556,805

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,556,805

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     6.8%

    12  

     Type of Reporting Person

     

     OO (Limited Liability Company)

     

     


    CUSIP No. N69605108    Schedule 13G    Page 3 of 6

     

    ITEM 1.

    (a)   Name of Issuer:

    Pharvaris, N.V. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    J.H. Oortweg 21, 2333 CH Leiden, The Netherlands

     

    ITEM 2.

    (a)   Name of Person Filing:

    This statement is being filed on behalf of LSP V Coöperatieve U.A. (“LSP V”) and LSP V Management B.V. (each a “Reporting Person” and, collectively, the “Reporting Persons”).

     

      (b)

    Address or Principal Business Office:

    The business address of the Reporting Persons is Johannes Vermeerplein 9, 1071 DV Amsterdam, The Netherlands.

     

      (c)

    Citizenship of each Reporting Person is:

    Each of the Reporting Persons is organized under the laws of The Netherlands. 

     

      (d)

    Title of Class of Securities:

    Ordinary Shares, par value € 0.12 per share (“Ordinary Shares”).

     

      (e)

    CUSIP Number:

    N69605108

     

    ITEM 3.

    Not applicable.

     

    ITEM 4.

    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of Ordinary Shares of the Issuer as of December 31, 2023, based upon 52,108,675 Ordinary Shares outstanding as reported by the Issuer in its prospectus supplement filed with the Securities and Exchange Commission pursuant to Rule 424(b)(5) on December 7, 2023.


    CUSIP No. N69605108    Schedule 13G    Page 4 of 6

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

       

    Sole power
    to vote or to
    direct the

    vote:

         Shared power
    to vote or to
    direct the vote:
        

    Sole

    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    LSP V Coöperatieve U.A.

         3,556,805        6.8 %      0        3,556,805        0        3,556,805  

    LSP V Management B.V

         3,556,805        6.8 %      0        3,556,805        0        3,556,805  

    LSP V is the record holder of 3,556,805 Ordinary Shares. LSP V Management B.V. is the sole director of LSP V. The managing directors of LSP V Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP V Management B.V., Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to beneficially own the Ordinary Shares held of record by LSP V. Each of Mr. Kleijwegt, Mr. Kuijten and Mr. Rothe disclaims beneficial ownership of such shares.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    Not applicable.


    CUSIP No. N69605108    Schedule 13G    Page 5 of 6

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 8, 2024

     

    LSP V Coöperatieve U.A.
    By:  

    /s/ Martijn Kleijwegt

    Name: LSP V Management B.V.
    Title: Managing Director
    Name: Martijn Kleijwegt
    Title: Managing Director
    By:  

    /s/ René Kuijten

    Name: LSP V Management B.V.
    Title: Managing Director
    Name: René Kuijten
    Title: Managing Director
    LSP V Management B.V.
    By:  

    /s/ Martijn Kleijwegt

    Name: Martijn Kleijwegt
    Title: Managing Director
    By:  

    /s/ René Kuijten

    Name: René Kuijten
    Title: Managing Director


    CUSIP No. N69605108    Schedule 13G    Page 6 of 6

     

    LIST OF EXHIBITS

     

    Exhibit
    No.

      

    Description

    99    Joint Filing Agreement (previously filed).
    Get the next $PHVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHVS

    DatePrice TargetRatingAnalyst
    4/29/2025$28.00Overweight
    Cantor Fitzgerald
    9/25/2023$27.00Outperform
    Wedbush
    8/15/2023$10.00 → $34.00Equal-Weight → Overweight
    Morgan Stanley
    10/5/2022$16.00Buy
    Bryan Garnier
    9/13/2022$34.00 → $18.00Mkt Outperform
    JMP Securities
    8/23/2022$40.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    8/22/2022$26.00 → $13.00Neutral → Underperform
    BofA Securities
    5/25/2022$34.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $PHVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Orphan medicinal product designation granted to deucrictibant in Europe for the treatment of bradykinin-mediated angioedemaData presented at recent congresses reinforces the value of deucrictibant by highlighting its ability to maintain a reduced attack rate in long-term prophylaxis, and potential to rapidly and completely treat HAE attacks, including in participants experiencing upper-ai

      4/7/25 6:58:03 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

      ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykinin-mediated angioedema. The U.S. Food and Drug Administration (FDA) previously granted orphan drug designation to deucrictibant for the treatment of bradykinin-mediated angioedema in M

      4/1/25 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

      Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero daysAll participants in CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of lifeOngoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks; median time to onset of symptom relief was 0.9 hours (N=7)In both extension studies, deucrictibant was generally well tolerated with no safety signals observed ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradyki

      3/3/25 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Financials

    Live finance-specific insights

    See more
    • Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

      CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece

      9/5/24 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

      Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo92.3% reduction in occurrence of moderate and severe attacks92.6% fewer attacks treated with on-demand medication by participantsDeucrictibant well-toleratedPharvaris to host a conference call today at 8:00 a.m. EST ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoi

      12/6/23 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

      Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks. Pharvaris plans to present data from the study at future medical meetings. RAPIDe-1 Clinical Stu

      12/8/22 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    SEC Filings

    See more
    • SEC Form 6-K filed by Pharvaris N.V.

      6-K - Pharvaris N.V. (0001830487) (Filer)

      4/7/25 6:51:03 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Pharvaris N.V.

      20-F - Pharvaris N.V. (0001830487) (Filer)

      4/7/25 6:50:27 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Pharvaris N.V.

      6-K - Pharvaris N.V. (0001830487) (Filer)

      1/13/25 6:51:02 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Pharvaris N.V. with a new price target

      Cantor Fitzgerald initiated coverage of Pharvaris N.V. with a rating of Overweight and set a new price target of $28.00

      4/29/25 8:11:22 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Pharvaris N.V. with a new price target

      Wedbush initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $27.00

      9/25/23 7:40:10 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris N.V. upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Pharvaris N.V. from Equal-Weight to Overweight and set a new price target of $34.00 from $10.00 previously

      8/15/23 7:24:38 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/14/24 8:42:52 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/14/24 10:27:18 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/13/24 2:14:59 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

      ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities

      11/15/23 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update

      Formal letters received from FDA relating to the previously announced hold on clinical studies of PHA121 in the U.S.Top-line data anticipated in 4Q22 for RAPIDe-1, a global Phase 2 study of PHVS416 for the acute treatment of HAE attacks ongoing outside the U.S.Executing from a strong financial position with cash and cash equivalents of €201 million as of June 30, 2022 ZUG, Switzerland, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the second quarter ended June 30, 2022, and provided a business update

      9/12/22 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care